Breaking News Instant updates and real-time market news.

VNDA

Vanda Pharmaceuticals

$14.95

-0.15 (-0.99%)

, HKMPY

Hikma

$34.30

(0.00%)

12:03
04/13/18
04/13
12:03
04/13/18
12:03

Vanda wins appeal case over patent infringement for Fanapt

Vanda Pharmaceuticals (VNDA) announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals (HKMPY), infringed Vanda's U.S. Patent number 8,586,610 for Fanapt. The '610 Patent is set to expire November 2, 2027.

VNDA

Vanda Pharmaceuticals

$14.95

-0.15 (-0.99%)

HKMPY

Hikma

$34.30

(0.00%)

  • 08

    May

VNDA Vanda Pharmaceuticals
$14.95

-0.15 (-0.99%)

09/14/17
PIPR
09/14/17
NO CHANGE
Target $26
PIPR
Overweight
Vanda price target raised to $26 from $23 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Vanda Pharmaceuticals to $26 saying the company's Phase II results with tradipitant in chronic pruritus associated with atopic dermatitis were positive. While the primary endpoint of change in average itch score did not reach statistical significance due to an uncooperative control arm, issues with reporting and variability on this endpoint make that not a surprise, Duncan tells investors in a research note. He feels that the totality of data "clearly show" activity in an all-comers atopic derm sample. The analyst keeps an Overweight rating on Vanda.
10/30/17
OPCO
10/30/17
NO CHANGE
Target $26
OPCO
Outperform
Vanda price target raised to $26 from $21 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target for Vanda to $26 from $21 based on his more bullish Hetlioz forecasts. The analyst believes the recent pullback provides a nice entry point for investors as he expects base business growth to accelerate in the next 12-18 months. Archila reiterates an Outperform rating on the shares.
11/13/17
OPCO
11/13/17
NO CHANGE
Target $25
OPCO
Outperform
Vanda selloff overdone, says Oppenheimer at Oppenheimer
Oppenheimer analyst Derek Archila believes the selloff post Q3 earnings is overdone and that fear of slowing Hetlioz volumes/sales is overblown. While there were some certain impacts to Hetlioz growth during Q3, the analyst continues to look at the bigger picture for the drug, particularly among sighted Non-24 patients which we view as a big opportunity. Archila would be a buyer, and retains high conviction on Hetlioz sales acceleration over the next 12-18 months and expect further upside. He reiterates an Outperform rating on the shares, while lowering his price target on the shares to $25 from $26.
01/19/18
GHSC
01/19/18
INITIATION
Target $20
GHSC
Buy
Vanda initiated with a Buy at Seaport Global
Seaport Global analyst Corey David initiated Vanda with a Buy and $20 price target. David said the long-term cash-flows from Fanapt and Hetlioz alone should be able to justify the current valuation, and potential upside would come with success on tradipitant on either one of its two indications being studied in the clinic.
HKMPY Hikma
$34.30

(0.00%)

05/17/17
JEFF
05/17/17
DOWNGRADE
JEFF
Underperform
Hikma downgraded to Underperform from Buy at Jefferies
Price target lowered to 1,450p.
08/21/17
JEFF
08/21/17
UPGRADE
JEFF
Hold
Hikma upgraded to Hold from Underperform at Jefferies
Jefferies analyst James Vane-Tempest upgraded Hikma to Hold from Underperform, saying its fundamentals are now skewed more to the upside than the downside. However, he lowered his price target on Hikma to 1,045p from 1,390p.
08/21/17
GSCO
08/21/17
DOWNGRADE
GSCO
Neutral
Hikma downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Yulia Gerasimova downgraded Hikma to Neutral from Buy and removed Hikma from Goldman's Pan-Europe Buy List, citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company.
08/22/17
08/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Mylan (MYL) downgraded to Hold from Buy at Argus with analyst Jasper Hellweg citing the cut in 2017 guidance. He said Mylan may also have difficulty improving operations in the near-term due to unfavorable EpiPen regulatory developments, pricing pressures, and increased competition. 2. Brookfield (BIP) downgraded to Neutral from Outperform at Credit Suisse, with analyst Andrew Kuske saying he is exiting his long "tactical trade" given recent outperformance. 3. Global Medical REIT (GMRE) downgraded to Neutral from Buy at DA Davidson with analyst Barry Oxford saying that the stock "could be range bound for a period of time" following the departures of the REIT's CEO and CFO and due to "potential concerns regarding the dividend and acquisitions." 4. NxStage Medical (NXTM) downgraded to Market Perform from Outperform at Leerink, as analyst Danielle Antalffy said it is unlikely another bidder will top Fresenius Medical's (FMS) $30 per share offer for the company. 5. Hikma (HKMPY) downgraded to Neutral from Buy at Goldman Sachs, with analyst Yulia Gerasimova citing Roxane integration issues, delayed generic Advair approval, ongoing U.S. generics pricing erosion, and multiple guidance downgrades from the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

RDC

Rowan Companies

$17.94

-0.08 (-0.44%)

08:13
10/22/18
10/22
08:13
10/22/18
08:13
Hot Stocks
Rowan Stavanger awarded contract by Equinor »

Rowan Companies announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

PETS

PetMed Express

$28.00

-0.8 (-2.78%)

08:12
10/22/18
10/22
08:12
10/22/18
08:12
Earnings
PetMed Express reports Q2 EPS 52c, consensus 50c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

SXT

Sensient

$64.37

-12.3 (-16.04%)

08:12
10/22/18
10/22
08:12
10/22/18
08:12
Recommendations
Sensient analyst commentary  »

Sensient price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLL

Full House Resorts

$2.70

-0.07 (-2.53%)

08:12
10/22/18
10/22
08:12
10/22/18
08:12
Hot Stocks
Full House Resorts receives acquisition proposal for $132.5M »

Full House Resorts has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$28.73

-2.83 (-8.97%)

08:11
10/22/18
10/22
08:11
10/22/18
08:11
Hot Stocks
eBay launches new program for consumers to instantly sell smartphones »

For consumers looking for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 03

    Mar

HRI

Herc Holdings

$34.75

-0.64 (-1.81%)

08:11
10/22/18
10/22
08:11
10/22/18
08:11
Upgrade
Herc Holdings rating change  »

Herc Holdings upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RS

Reliance Steel

$81.10

-0.27 (-0.33%)

08:11
10/22/18
10/22
08:11
10/22/18
08:11
Downgrade
Reliance Steel rating change  »

Reliance Steel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PM

Philip Morris

$88.83

1.35 (1.54%)

08:10
10/22/18
10/22
08:10
10/22/18
08:10
Periodicals
Philip Morris lauching anti-smoking campaign, CNBC reports »

Philip Morris has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PMBC

Pacific Mercantile Bancorp

$8.34

0.04 (0.48%)

08:10
10/22/18
10/22
08:10
10/22/18
08:10
Earnings
Pacific Mercantile Bancorp reports Q3 EPS 17c, two estimates 16c »

Reports Q3 CET1 ratio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 27

    Nov

HON

Honeywell

$153.49

-1.73 (-1.11%)

08:10
10/22/18
10/22
08:10
10/22/18
08:10
Recommendations
Honeywell analyst commentary  »

Honeywell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URI

United Rentals

$117.15

-0.94 (-0.80%)

08:10
10/22/18
10/22
08:10
10/22/18
08:10
Hot Stocks
United Rentals acquires WesternOne Rentals & Sales for $91.8M in cash »

United Rentals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$192.83

-3.91 (-1.99%)

08:10
10/22/18
10/22
08:10
10/22/18
08:10
Earnings
Lennox sees FY19 impact of tornado approximately $85M of revenue »

Estimating 2019 tornado…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AAPL

Apple

$219.28

3.3 (1.53%)

08:09
10/22/18
10/22
08:09
10/22/18
08:09
Recommendations
Apple analyst commentary  »

Apple iPhone pricing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZAYO

Zayo Group

$31.97

0.01 (0.03%)

08:09
10/22/18
10/22
08:09
10/22/18
08:09
Hot Stocks
Major retailer selects Zayo for nationwide network »

A major retailer has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

ARCE

Arco Platform

$22.91

-0.04 (-0.17%)

08:09
10/22/18
10/22
08:09
10/22/18
08:09
Initiation
Arco Platform initiated  »

Arco Platform initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBPH

Theravance Biopharma

$29.16

-0.14 (-0.48%)

08:08
10/22/18
10/22
08:08
10/22/18
08:08
Hot Stocks
Theravance Biopharma reports data from TD-1473 Phase 1b study »

Theravance Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 27

    Nov

  • 18

    Dec

TCF

TCF Financial

$22.45

-0.43 (-1.88%)

08:08
10/22/18
10/22
08:08
10/22/18
08:08
Earnings
TCF Financial reports Q3 EPS 51c, consensus 48c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 15

    Nov

BMRC

Bank of Marin

$79.52

0.41 (0.52%)

08:08
10/22/18
10/22
08:08
10/22/18
08:08
Earnings
Bank of Marin reports Q3 EPS $1.23, consensus $1.17 »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

MLNT

Melinta Therapeutics

$3.79

-0.01 (-0.26%)

, AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

08:07
10/22/18
10/22
08:07
10/22/18
08:07
Hot Stocks
Melinta Therapeutics CEO Dan Wechsler steps down, John Johnson named interim »

Melinta Therapeutics…

MLNT

Melinta Therapeutics

$3.79

-0.01 (-0.26%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

PTLA

Portola Pharmaceuticals

$21.92

-0.55 (-2.45%)

SBBP

Strongbridge Biopharma

$4.87

-0.1 (-2.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Nov

  • 31

    Dec

CRBP

Corbus Pharmaceuticals

$7.26

-0.54 (-6.92%)

08:06
10/22/18
10/22
08:06
10/22/18
08:06
Hot Stocks
Corbus data shows 'favorable' safety profiles maintained with Lenabasum »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KSU

Kansas City Southern

$106.14

3.455 (3.36%)

08:05
10/22/18
10/22
08:05
10/22/18
08:05
Upgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

BSRR

Sierra Bancorp

$26.96

-0.06 (-0.22%)

08:05
10/22/18
10/22
08:05
10/22/18
08:05
Earnings
Sierra Bancorp reports Q3 EPS 46c, consensus 47c »

Reports Q3 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

, GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

08:04
10/22/18
10/22
08:04
10/22/18
08:04
Hot Stocks
Tendril, Google collaborate for energy info for Indiana Michigan Power customers »

Tendril announced a new…

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

AEP

American Electric

$73.25

1.55 (2.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 11

    Nov

  • 11

    Nov

  • 03

    Mar

ETTX

Entasis Therapeutics

$7.44

0.34 (4.79%)

08:04
10/22/18
10/22
08:04
10/22/18
08:04
Initiation
Entasis Therapeutics initiated  »

Entasis Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$192.83

-3.91 (-1.99%)

08:04
10/22/18
10/22
08:04
10/22/18
08:04
Hot Stocks
Breaking Hot Stocks news story on Lennox »

Lennox plans $100M of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.